Nicolas C.
- Country
- France
- Department
- Hématologie clinique et oncologie médicale
Research Overview
- IFCT-2201 ADAPTABLE A non-comparative randomized phase II trial evaluating the combination of paclitaxel-bevacizumab ± atezolizumab in patients with advanced non-squamous NSCLC progressing after immunotherapy and chemotherapy
- A Phase 2, Multicenter, Randomized Study to Compare the Efficacy and Safety of MK-7684A or MK-7684A Plus Docetaxel Versus Docetaxel Monotherapy in the Treatment of Participants With Metastatic Non-small Cell Lung Cancer With Progressive Disease After Treatment With a Platinum Doublet Chemotherapy and Immunotherapy
- Phase II Study of Rilvegostomig and Ramucirumab in Combination Therapy for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Data & Insights
Has run more than one trial at 264 of 499 partner sites.
Specializations
Non-Small Cell Lung Cancer Research
The investigator specializes in studying advanced treatments for non-small cell lung cancer (NSCLC), with particular focus on both early-stage and metastatic disease. Their research encompasses innovative therapeutic approaches for patients with various NSCLC subtypes, including squamous and non-squamous variants.
- Resectable early-stage NSCLC treatment
- Metastatic NSCLC management
- PD-L1 expressing tumors
Immunotherapy Applications
Primary research focus includes investigating novel immunotherapy combinations and targeted treatments. The investigator studies various immunotherapeutic agents including durvalumab, pembrolizumab, and emerging compounds like tiragolumab and volrustomig.
- Neoadjuvant immunotherapy
- Combination immunotherapy approaches
- Novel immunotherapy agents
Specialized Treatment Approaches
The investigator explores targeted therapies for specific patient populations, including those with KRAS G12C mutations and EGFR mutations. Research extends to small cell lung cancer (SCLC) with particular attention to molecular markers like SLFN11.
- Mutation-specific treatments
- Elderly patient populations
- Biomarker-driven therapies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.